Maura Campbell
President & CEO
OBIO
Dr. Maura Campbell is the President and CEO of OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization. Dr. Campbell has more than 30 years of experience in all key areas of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations.
With expertise in technology transfer and commercialization of intellectual property, Dr. Campbell has held various roles in senior management, most recently as the Vice-President of Intellectual Property and Contracts for Turnstone Biologics, which went public on the NASDAQ. Previously, Dr. Campbell served as: Director, Intellectual Property at VBI Vaccines; Research Program Manager, and Manager of Technology Transfer & Commercialization at the Ottawa Hospital Research Institute; Director of Intellectual Property for PainCeptor Pharma Corporation; and Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems National Centre of Excellence. Dr. Campbell has also served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs.
Dr. Campbell received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston. Dr. Campbell served as the Vice-Chair of Ontario’s Life Sciences Council, supporting a plan to make Ontario a top hub for innovation growth and life sciences investment. She currently serves as a board member for FACIT (a business accelerator and investor established by the Ontario Institute for Cancer Research), SPEC Labs (a life sciences incubator and healthcare & life sciences innovation hub) and Intellectual Property Ontario (a provincial agency providing trusted IP support for Ontario innovators). Dr. Campbell is also the Co-Founder, Managing Director- External Relations & Expert-In-Residence of Capital BioVentures (an Ottawa Canada founded wet-lab accelerator program).
With expertise in technology transfer and commercialization of intellectual property, Dr. Campbell has held various roles in senior management, most recently as the Vice-President of Intellectual Property and Contracts for Turnstone Biologics, which went public on the NASDAQ. Previously, Dr. Campbell served as: Director, Intellectual Property at VBI Vaccines; Research Program Manager, and Manager of Technology Transfer & Commercialization at the Ottawa Hospital Research Institute; Director of Intellectual Property for PainCeptor Pharma Corporation; and Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems National Centre of Excellence. Dr. Campbell has also served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs.
Dr. Campbell received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston. Dr. Campbell served as the Vice-Chair of Ontario’s Life Sciences Council, supporting a plan to make Ontario a top hub for innovation growth and life sciences investment. She currently serves as a board member for FACIT (a business accelerator and investor established by the Ontario Institute for Cancer Research), SPEC Labs (a life sciences incubator and healthcare & life sciences innovation hub) and Intellectual Property Ontario (a provincial agency providing trusted IP support for Ontario innovators). Dr. Campbell is also the Co-Founder, Managing Director- External Relations & Expert-In-Residence of Capital BioVentures (an Ottawa Canada founded wet-lab accelerator program).
Canada’s Life Sciences Summit
Contact Us
Links
Get in Touch
NGBi © 2025. All rights reserved.